logo
Plus   Neg
Share
Email

Expedia Appoints Alan Pickerill As EVP And CFO

Expedia Inc. (EXPE) announced that its Board has approved the appointment of Alan Pickerill, currently Senior Vice President, Treasurer and Head of Investor Relations, to succeed Mark Okerstrom as Executive Vice President and Chief Financial Officer.

As announced previously, Okerstrom has been appointed to the role of President and Chief Executive Officer.

Pickerill has deep finance and accounting experience spanning nearly 30 years. He began his career as an accountant at Deloitte and Touche where he practiced for seven years before moving onto progressively senior finance leadership roles at a variety of publicly traded technology and internet companies including roles at Microsoft and Getty Images. Pickerill joined Expedia in 2008, took over leadership of Investor Relations function in 2010, and added Global Treasury to his remit in 2015. He currently sits on Expedia, Inc.'s, Disclosure Practices and Foreign Exchange Review Committees.

Earlier This week, Uber's board selected Dara Khosrowshahi, the head of travel booking website Expedia, to be its new chief executive officer.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT